GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled, Nir; Gillis, Roni; KILIÇKAP, SAADETTİN; Froesch, Patrizia; Orlov, Sergei; Filippova, Elena; Demirci, Umut; Christopoulos, Petros; ÇİÇİN, İRFAN; Basal, Fatma; Yilmaz, Cengiz; Fedor, Moiseenko; KORKMAZ, Taner; Paydas, Semra; Gautschi, Oliver; Zirtiloglu, Alisan; ERALP, YEŞİM; Cinkir, Havva; Sezer, Ahmet; ERMAN, MUSTAFA; Tural, DENİZ; TURNA, Zeynep; Mazieres, Julien; Dudnik, Elizabeth; Reguart, Noemi; Camidge, David; Ng, Terry; Senler, Filiz; Beypinar, Ismail; Yazilitas, Dogan; Demirkazik, Ahmet; Karaoglu, Aziz; Okutur, Kerem; Coskun, HASAN; Sendur, Mehmet; Isikdogan, Abdurrahman; ÇABUK, DEVRİM; Yumuk, Perran; YILDIZ, İbrahim; Kaplan, M.; ÖZYILKAN, ÖZGÜR; Oztop, Ilhan; Olmez, Omer; Aydin, Kubra; Aydiner, Adnan; Meydan, Nezih; Grinberg, Roxana; Roisman, Laila

doi:10.1016/j.lungcan.2020.07.022

GLASS: Global Lorlatinib for ALK(+) and ROS1(+) retrospective Study: real world data of 123 NSCLC patients

Peled N., Gillis R., KILIÇKAP S., Froesch P., Orlov S., Filippova E., ...More

LUNG CANCER, vol.148, pp.48-54, 2020 (SCI-Expanded, Scopus)

Publication Type: Article / Article
Volume: 148
Publication Date: 2020
Doi Number: 10.1016/j.lungcan.2020.07.022
Journal Name: LUNG CANCER
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, PASCAL, EMBASE, MEDLINE
Page Numbers: pp.48-54
Keywords: Lorlatinib, Real-world data, ALK, ROS1, CELL LUNG-CANCER, HYBRID CAPTURE, SINGLE-ARM, OPEN-LABEL, CRIZOTINIB, REARRANGEMENT, IMMUNOHISTOCHEMISTRY, MULTICENTER, CRITERIA, RET
Akdeniz University Affiliated: Yes

Abstract

Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.